Home     Useful Links     Promotion Activities     Contact          ?????

Organisation active in
ICT, Electronic, Telecomm135 
Ind. Technology, Material176 
Energy162 
Security & Environment225 
Transport & Aeronautics57 
Food & Agriculture206 
Biotech & Medicine265 
Technical sciences87 
None technical209 

 Organisation Profiles
 Serbia449 
 Montenegro43 
 Bosnia-Herzegovina179 
 FYR of Macedonia242 
 Croatia70 
 Albania35 
 Other24 
 Total1042 

 Profiles accessed
 Today358  
 Last week5089  
 Last month20657  
 Last year193938  

Prepare for printing     
University Clinic for Radiotherapy and Oncology
Medical Faculty

 Contact data
StreetVodnjanska 17 
ZIP, City, State 1000 - Skopje (FYR of Macedonia) 
Phone+389 2 313 72 12 
Fax+389 2 313 72 12 
Emailsmicko@t-home.mk 
 Contact person

Professor Dr. PhD Snezana Smickoska (Chief of the Departement)
 Employees in RTD
51-100
 Activities in Research and Development

 RTD sectors:
» Medicine and Health     

 Area of expertise (keywords)
» Radiation therapy, oncology, breast cancer
 RTD Experiences

 RTD focus of organization
Radiotherapy and chemotherapy

 Description of RTD activities
Involved in clinical international trials considering radiotherapy, chemotherapy and targeted therapy of malignant diseases

 Experiences in international Programmes
1. Phase II study evaluating efficacy and safety of doxorubicin plus Taxol (paclitaxel) combination as first line treatment for patients with metastatic breast cancer
(Prospective, phase II single center study-2000)

2. The International Adjuvant Lung Cancer Trial Collaborative Group. CISPLATIN-BASED ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL-CELL LUNG CANCER. The New England Journal of Medicine, Vol.350, No.4, 351-360, 2004
(A large scale trial evaluating adjuvant chemotherapy after curative resection of non-small cell lung cancer-June 1995)

3. A Phase III study of DPPE (Tesmilifene) combine with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as first line Treatment in Metastatic/Recurrent Breast Cancer Pharm-Olam YMB 1002 - 02 Study (2005, on-going)

4. An expanded program of TarcevaTM (erlotinib, OSI-774) in treatment of patients with advanced stage IIIB/IV non-small-cell lung cancer
(An open-label, non-randomized, multicentre expanded access clinical trial of Tarceva as single agent, 2005, on-going)

5. Daily oral perifosine (ZEN-004) in combination with radiotherapy in non-small cell lung cancer patients (june 2007-on-going)

6. Project MAK /6/010 “Upgrading of radiotherapy Facilities and Introducing a New Radiotherapy Techniques in the FYR Macedonia” 2007-2009, IAEA

7. An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer (2008- on-going)

8. A non comparative, multicenter, repeat dose safety in use study of neukine (filgrastim) in patients receiving chemotherapy known to induce neutropenia. Protocol code: kwi 300 105 (2008- on-going)

 Organisation is/was involved in projects funded by the following RTD programmes
  Coordinator  Partner 
National RTD Programmes

 Inserted / Updated
2008-12-12 / 2010-04-14